



LMA International NV

FOR IMMEDIATE RELEASE

LMA EXPANDS PRODUCT OFFERING WITH ACQUISITION OF PAIN MANAGEMENT BUSINESS

- Latest acquisition is LMA's second in six months, underscoring intent to boost its product offering and strengthen its position as a leading anaesthesia-related medical device company

Singapore, 17 March 2008 – Singapore-listed LMA International N.V. (“LMA” or the “Group”), the global leader in the development and marketing of the LMA™ laryngeal mask airway range of supraglottic airway management devices, today announced that it has acquired the pain management business of Breg Inc. (“Breg”), a California-based provider of premium orthopedic, reconstructive and postoperative products and a subsidiary of Orthofix International N.V., a global diversified orthopedic products company listed on NASDAQ. This latest development follows the Group’s acquisition of the PerfectTemp®, an innovative patient warming device, in October 2007, in line with LMA’s strategy to acquire synergistic products and businesses to strengthen its position as a leading anaesthesia-related medical device company.

The Group’s wholly owned subsidiaries LMA North America Inc (“LMANA”) and LMA Medical Innovations Ltd. (“LMAMI”) will acquire all the intellectual property, related business assets and distribution rights to the Pain Care® range of ambulatory infusion pumps in the United States and International markets for a potential consideration of US\$6.88 million. An initial sum of US\$5.88 million is payable in cash on completion of the transaction, with the remaining sum to be paid based on the achievement of a revenue benchmark in the first six months post acquisition. The consideration was arrived at based on a willing buyer-willing seller basis and will be funded internally. LMA has entered into an agreement with Breg to secure the manufacturing of the device for a transitional period of up to 18 months post acquisition.

The Pain Care® ambulatory infusion pumps are designed to provide direct wound site pain relief without the side effects of narcotics. The pumps offer a continuous drip that automatically dispenses the appropriate amount of medication for easy, hands-free operation and aid in earlier ambulation, increased mobility, faster recovery and shorter hospital stays.

The total market size for ambulatory infusion pumps in the United States is estimated to be around US\$115.0 million and is expected to grow in size as healthcare organisations

continue to focus on lowering medical costs and shortening hospital stays for patients. Sales of ambulatory infusion pumps in the United States over the last 12 months amounted to US\$4.5 million. LMA expects to expand sales of this device to the international markets in FY2008.

Mr Steve Block, President and CEO of LMANA, said, "We are excited about the addition of ambulatory infusion pumps to our family of medical devices, especially as we can leverage the existing sales teams of our LMA airway management devices. This new device is also used by anesthesiologists and will strengthen our relationships with our existing customer base and group purchasing organisations as we can now offer a wider basket of products."

Added Mr John Lim, Executive Deputy Chairman of LMA, said, "This acquisition is in line with our strategy of acquiring potentially high growth products that share the same sales point-of-call as our core airway management business. We see Pain Management as a growth area and this acquisition will allow us to participate not only in general anesthesia but also in the rapidly growing regional anesthesia market."

Assuming the transaction had been completed at the beginning of the financial year ended 31 December 2007, this acquisition would not have had a material impact on the Group's earnings per share for that financial year. Net tangible assets acquired in the transaction amount to US\$0.8 million. In view of the goodwill included in the consideration and the intangible nature of intellectual property rights, this acquisition would have diluted the Group's net tangible assets per share as at 31 December 2007 by 9.9% had it been effected at the end of that financial year.

Mr Robert Gaines-Cooper, Group Chairman of LMA, is a former director and is currently a substantial shareholder of Orthofix International N.V.. Save as mentioned, no director or controlling shareholder of LMA has an interest, direct or indirect, in the transaction.

- Ends -

For media queries, please contact

Sharon Seetho/ Jeffrey Fang, Gavin Anderson & Company, Singapore, +65 6339 9110

About LMA

Incorporated in the Netherlands Antilles in 1998, LMA listed on the Mainboard of the Singapore Exchange in March 2005. LMA designs, develops, markets and distributes medical equipment, principally the LMA™ laryngeal mask airway range of supraglottic airway management devices. These devices are used by physicians to allow respiration, provide ventilation to, and support the airway of patients undergoing surgical procedures and life-saving interventions. Since its first product, the LMA Classic™, was approved by the FDA for use in the United States in 1991, LMA's growth has been driven by the development of innovative products, geographic expansion, and increased customer awareness of the LMA™ laryngeal mask airway as an alternative airway management device. LMA has established a leading position in this growing market.

LMA has an office in Jersey, Channel Islands, and subsidiaries in Singapore, Bonn, Germany, San Diego, California and Melbourne, Australia. Through its 50 percent joint venture in LMA Urology Limited, the Group has a subsidiary in Gland, Switzerland to design, manufacture and distribute the LMA StoneBreaker™. DBS Bank and Credit Suisse were the Joint Global Coordinators and Joint Bookrunners for the Initial Public Offering of shares in LMA.